| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00
CUPERTINO, Calif.—BioImagenerecently announced a collaboration deal with HP under which BioImagene'shigh-content analysis and digital pathology platforms will be bundled with HPservers. Financial and other business-related details have not been disclosed.
Some two-thirds of the data in the life sciences, drugdiscoveries and healthcare industries is in the form of images, so managing suchdata efficiently is a "mission critical" component for successful decisionmaking, according to Mohan Uttarwar, CEO of BioImagene. Adding to thechallenges is the fact that extracting meaningful information and knowledgefrom image data is still manual, inefficient and expensive, he adds.
The integration of BioImagene and HP technologies reportedlywill solve many of the problems in this area. And, according to Randy Chen, projectleader of research informatics at Allergan, one of BioImagene's customers whohas tried out the integrated technology, image management is indeed much easiernow.
"By implementing BioImagene's Image Management system on HPplatforms, we have enabled scientists to access images and research dataquickly and easily," Chen says. "The solution from BioImagene and HP isexpected to provide powerful hardware and image management expertise to the imageinformatics community and accelerate discovery research even more costefficiently."
"What this collaboration means to customers is gains both ingeneral efficiency and cost efficiency," notes Dr. Mat Rashidi, interim vicepresident of marketing and business development for BioImagene. "They can getfully integrated systems where the software and hardware both are fully testedand supported, providing peace of mind."
As for the timing of the deal, Rashidi says that the highcontent analysis and digital pathology markets are in high growth mode rightnow, and "this collaboration helps our total solution offerings in these hugemarkets."
BioImagene products include CellMine, which is focused onhigh-content analysis applications; TissueMine, which is geared toward digitalpathology; and 3i, which is an image management tool. "Various system configurations are possible, in termsof different sizes of servers and the various BioImagene products that might beintegrated with them," Rashidi notes. "A customer might want CellMine with arelatively modest server, or CellMine and TissueMine with an advanced server,or any number of other options."
 

About the Author

Related Topics

Published In

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

A blue x-ray style image of a human body is shown with the liver illuminated in orange against a dark blue background.

Harnessing liver-on-a-chip models for drug safety

Discover how researchers leverage microphysiological systems in toxicology studies.  
A person wearing a white lab coat types on a laptop with various overlaid enlarged files shown with plus signs on file folders floating over the laptop screen with a clinical lab shown in the background in grey and white tones.

Enhancing bioanalytical studies with centralized data management

Learn how researchers can improve compliance and efficiency with advanced LIMS solutions.
A 3D-rendered digital illustration of a molecular structure floating among red blood cells in a bloodstream environment.

Explained: How are metabolite biomarkers improving drug discovery and development?

By offering a rich source of insights into disease and drugs, metabolite biomarkers are at the forefront of therapeutic exploration.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue